Prognostic factors in patients with clinical stage I nonseminoma—beyond lymphovascular invasion: a systematic review

[1] Fosså SD(2011)Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients J Clin Oncol 29 963-970

[2] Cvancarova M(2020)Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumor: a systematic review and meta-analysis BJU Int 125 355-368

[3] Chen L(2014)One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group Ann Oncol 25 2167-72

[4] Allan AL(2019)Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: a population-based prospective cohort study PLoS ONE 14 1721-1724

[5] Oldenburg J(2000)Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection J Urol 163 51-57

[6] Peterson DR(2015)Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance J Clin Oncol 33 3817-3823

[7] Travis LB(2014)Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort J Clin Oncol 32 1505-12

[8] Blok JM(2003)Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial J Clin Oncol. 21 833-838

[9] Pluim I(2015)Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer Ann Oncol 26 169-80

[10] Daugaard G(2021)Management of germ cell tumors of the testis in adult patients. German clinical practice guideline part I: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages Urol Int 105 181-191

[1] Fosså SD(2011)Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients J Clin Oncol 29 963-970

[2] Cvancarova M(2020)Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumor: a systematic review and meta-analysis BJU Int 125 355-368

[3] Chen L(2014)One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group Ann Oncol 25 2167-72

[4] Allan AL(2019)Causes of inferior relative survival after testicular germ cell tumor diagnosed 1953–2015: a population-based prospective cohort study PLoS ONE 14 1721-1724

[5] Oldenburg J(2000)Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection J Urol 163 51-57

[6] Peterson DR(2015)Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance J Clin Oncol 33 3817-3823

[7] Travis LB(2014)Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort J Clin Oncol 32 1505-12

[8] Blok JM(2003)Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial J Clin Oncol. 21 833-838

[9] Pluim I(2015)Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer Ann Oncol 26 169-80

[10] Daugaard G(2021)Management of germ cell tumors of the testis in adult patients. German clinical practice guideline part I: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages Urol Int 105 181-191